Prognostic factors analysis of diffuse midline glioma
Purpose This study retrospectively analyzes cases of diffuse midline glioma treated with radiotherapy, with the aim of investigating the prognosis of the tumor and its influencing factors. Methods From January 2018 to November 2022, we treated 64 patients who were pathologically diagnosed with diffu...
Gespeichert in:
| Veröffentlicht in: | Journal of neuro-oncology 2024-04, Vol.167 (2), p.285-292 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 292 |
|---|---|
| container_issue | 2 |
| container_start_page | 285 |
| container_title | Journal of neuro-oncology |
| container_volume | 167 |
| creator | Jiang, Jing Li, Wen-bin Xiao, Shao-wen |
| description | Purpose
This study retrospectively analyzes cases of diffuse midline glioma treated with radiotherapy, with the aim of investigating the prognosis of the tumor and its influencing factors.
Methods
From January 2018 to November 2022, we treated 64 patients who were pathologically diagnosed with diffuse midline glioma. Among them, 41 underwent surgical resection, and 23 underwent biopsy procedures. All patients received postoperative radiotherapy. We followed up with the patients to determine the overall survival rate and conducted univariate and multivariate analyses on relevant indicators.
Results
The median survival time for the entire patient group was 33.3 months, with overall survival rates of 92.9%, 75.4%, and 45.0% at 1 year, 2 years, and 3 years, respectively. Univariate and multivariate analyses indicated that older patients had a better prognosis.
Conclusion
Patient age is an independent prognostic factor for patients with diffuse midline glioma undergoing radiation therapy. |
| doi_str_mv | 10.1007/s11060-024-04605-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11023999</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2929540398</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-e6e4b2704542aeae09042645a9d6b61415d62a9ffdfaab36c5c768f9cd3aa6de3</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhq0KRJdt_0APKBIXLoHxd3xCqOJLqtQeisTNmnXsxVUSL3aC1H-Pl13Kx6EnS55nXo_nIeSCwmsKoN8USkFBC0y0IBTIVp2QFZWat5pr_oSsgCrdSiO-npLnpdwBgNCcPiOnvOMdZVKviLzJaTulMkfXBHRzyqXBCYf7EkuTQtPHEJbimzH2Q5x8sx1iGvGMPA04FH9-PNfky4f3t5ef2qvrj58v3121TjA1t155sWEahBQMPXowUO-FRNOrjaKCyl4xNCH0AXHDlZNOqy4Y13NE1Xu-Jm8PubtlM_re-WnOONhdjiPme5sw2n8rU_xmt-mHrZth3BhTE14dE3L6vvgy2zEW54cBJ5-WYplhRgrgpqvoy__Qu7TkuotiOQigQnVUVYodKJdTKdmHh2ko2L0We9Biqxb7S4vdN734-x8PLb89VIAfgFJL09bnP28_EvsT7laYug</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3040146816</pqid></control><display><type>article</type><title>Prognostic factors analysis of diffuse midline glioma</title><source>SpringerLink Journals - AutoHoldings</source><creator>Jiang, Jing ; Li, Wen-bin ; Xiao, Shao-wen</creator><creatorcontrib>Jiang, Jing ; Li, Wen-bin ; Xiao, Shao-wen</creatorcontrib><description>Purpose
This study retrospectively analyzes cases of diffuse midline glioma treated with radiotherapy, with the aim of investigating the prognosis of the tumor and its influencing factors.
Methods
From January 2018 to November 2022, we treated 64 patients who were pathologically diagnosed with diffuse midline glioma. Among them, 41 underwent surgical resection, and 23 underwent biopsy procedures. All patients received postoperative radiotherapy. We followed up with the patients to determine the overall survival rate and conducted univariate and multivariate analyses on relevant indicators.
Results
The median survival time for the entire patient group was 33.3 months, with overall survival rates of 92.9%, 75.4%, and 45.0% at 1 year, 2 years, and 3 years, respectively. Univariate and multivariate analyses indicated that older patients had a better prognosis.
Conclusion
Patient age is an independent prognostic factor for patients with diffuse midline glioma undergoing radiation therapy.</description><identifier>ISSN: 0167-594X</identifier><identifier>ISSN: 1573-7373</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-024-04605-6</identifier><identifier>PMID: 38381257</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Age ; Biopsy ; Blood ; Brain cancer ; Cancer therapies ; Chemotherapy ; Digital transmission ; Glioma ; Hospitals ; Medical prognosis ; Medicine ; Medicine & Public Health ; Mutation ; Nervous system ; Neurology ; Oncology ; Patients ; Pediatrics ; Prognosis ; Radiation therapy ; Spinal cord ; Survival ; Tumors</subject><ispartof>Journal of neuro-oncology, 2024-04, Vol.167 (2), p.285-292</ispartof><rights>The Author(s) 2024. corrected publication 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. corrected publication 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024, corrected publication 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c426t-e6e4b2704542aeae09042645a9d6b61415d62a9ffdfaab36c5c768f9cd3aa6de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11060-024-04605-6$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11060-024-04605-6$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38381257$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jiang, Jing</creatorcontrib><creatorcontrib>Li, Wen-bin</creatorcontrib><creatorcontrib>Xiao, Shao-wen</creatorcontrib><title>Prognostic factors analysis of diffuse midline glioma</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><addtitle>J Neurooncol</addtitle><description>Purpose
This study retrospectively analyzes cases of diffuse midline glioma treated with radiotherapy, with the aim of investigating the prognosis of the tumor and its influencing factors.
Methods
From January 2018 to November 2022, we treated 64 patients who were pathologically diagnosed with diffuse midline glioma. Among them, 41 underwent surgical resection, and 23 underwent biopsy procedures. All patients received postoperative radiotherapy. We followed up with the patients to determine the overall survival rate and conducted univariate and multivariate analyses on relevant indicators.
Results
The median survival time for the entire patient group was 33.3 months, with overall survival rates of 92.9%, 75.4%, and 45.0% at 1 year, 2 years, and 3 years, respectively. Univariate and multivariate analyses indicated that older patients had a better prognosis.
Conclusion
Patient age is an independent prognostic factor for patients with diffuse midline glioma undergoing radiation therapy.</description><subject>Age</subject><subject>Biopsy</subject><subject>Blood</subject><subject>Brain cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Digital transmission</subject><subject>Glioma</subject><subject>Hospitals</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mutation</subject><subject>Nervous system</subject><subject>Neurology</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Spinal cord</subject><subject>Survival</subject><subject>Tumors</subject><issn>0167-594X</issn><issn>1573-7373</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp9kU1v1DAQhq0KRJdt_0APKBIXLoHxd3xCqOJLqtQeisTNmnXsxVUSL3aC1H-Pl13Kx6EnS55nXo_nIeSCwmsKoN8USkFBC0y0IBTIVp2QFZWat5pr_oSsgCrdSiO-npLnpdwBgNCcPiOnvOMdZVKviLzJaTulMkfXBHRzyqXBCYf7EkuTQtPHEJbimzH2Q5x8sx1iGvGMPA04FH9-PNfky4f3t5ef2qvrj58v3121TjA1t155sWEahBQMPXowUO-FRNOrjaKCyl4xNCH0AXHDlZNOqy4Y13NE1Xu-Jm8PubtlM_re-WnOONhdjiPme5sw2n8rU_xmt-mHrZth3BhTE14dE3L6vvgy2zEW54cBJ5-WYplhRgrgpqvoy__Qu7TkuotiOQigQnVUVYodKJdTKdmHh2ko2L0We9Biqxb7S4vdN734-x8PLb89VIAfgFJL09bnP28_EvsT7laYug</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Jiang, Jing</creator><creator>Li, Wen-bin</creator><creator>Xiao, Shao-wen</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240401</creationdate><title>Prognostic factors analysis of diffuse midline glioma</title><author>Jiang, Jing ; Li, Wen-bin ; Xiao, Shao-wen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-e6e4b2704542aeae09042645a9d6b61415d62a9ffdfaab36c5c768f9cd3aa6de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Age</topic><topic>Biopsy</topic><topic>Blood</topic><topic>Brain cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Digital transmission</topic><topic>Glioma</topic><topic>Hospitals</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mutation</topic><topic>Nervous system</topic><topic>Neurology</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Spinal cord</topic><topic>Survival</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiang, Jing</creatorcontrib><creatorcontrib>Li, Wen-bin</creatorcontrib><creatorcontrib>Xiao, Shao-wen</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiang, Jing</au><au>Li, Wen-bin</au><au>Xiao, Shao-wen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic factors analysis of diffuse midline glioma</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><addtitle>J Neurooncol</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>167</volume><issue>2</issue><spage>285</spage><epage>292</epage><pages>285-292</pages><issn>0167-594X</issn><issn>1573-7373</issn><eissn>1573-7373</eissn><abstract>Purpose
This study retrospectively analyzes cases of diffuse midline glioma treated with radiotherapy, with the aim of investigating the prognosis of the tumor and its influencing factors.
Methods
From January 2018 to November 2022, we treated 64 patients who were pathologically diagnosed with diffuse midline glioma. Among them, 41 underwent surgical resection, and 23 underwent biopsy procedures. All patients received postoperative radiotherapy. We followed up with the patients to determine the overall survival rate and conducted univariate and multivariate analyses on relevant indicators.
Results
The median survival time for the entire patient group was 33.3 months, with overall survival rates of 92.9%, 75.4%, and 45.0% at 1 year, 2 years, and 3 years, respectively. Univariate and multivariate analyses indicated that older patients had a better prognosis.
Conclusion
Patient age is an independent prognostic factor for patients with diffuse midline glioma undergoing radiation therapy.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>38381257</pmid><doi>10.1007/s11060-024-04605-6</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-594X |
| ispartof | Journal of neuro-oncology, 2024-04, Vol.167 (2), p.285-292 |
| issn | 0167-594X 1573-7373 1573-7373 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11023999 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Age Biopsy Blood Brain cancer Cancer therapies Chemotherapy Digital transmission Glioma Hospitals Medical prognosis Medicine Medicine & Public Health Mutation Nervous system Neurology Oncology Patients Pediatrics Prognosis Radiation therapy Spinal cord Survival Tumors |
| title | Prognostic factors analysis of diffuse midline glioma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T22%3A59%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20factors%20analysis%20of%20diffuse%20midline%20glioma&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Jiang,%20Jing&rft.date=2024-04-01&rft.volume=167&rft.issue=2&rft.spage=285&rft.epage=292&rft.pages=285-292&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-024-04605-6&rft_dat=%3Cproquest_pubme%3E2929540398%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3040146816&rft_id=info:pmid/38381257&rfr_iscdi=true |